Amanote Research
Register
Sign In
155P: PD-L1 Polymorphism Can Predict Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated With First-Line Paclitaxel–cisplatin Chemotherapy
Journal of Thoracic Oncology
- United States
doi 10.1016/s1556-0864(16)30265-9
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
April 1, 2016
Authors
S.K. Do
S.Y. Lee
J.E. Choi
M.J. Hong
J.H. Lee
J.Y. Park
Publisher
Elsevier BV
Related search
P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients
British Journal of Cancer
Cancer Research
Oncology
PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Clinical Significance of miRNA - 106a in Non-Small Cell Lung Cancer Patients Who Received Cisplatin Combined With Gemcitabine Chemotherapy
Cancer Biology and Medicine
Cancer Research
Oncology
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PD-L1 and Immunotherapy in Patients With Non-Small Cell Lung Cancer and Malignant Pleural Effusion
